Early Detection of Alzheimer’s: Blood Test Meets Digital App
How the Two Technologies Work Together
A partnership between Circular Genomics and Altoida has produced a combined approach that uses a blood test and a ten‑minute cognitive app to spot Alzheimer’s disease earlier than current methods allow. The collaboration was announced this week and aims to identify the disease before significant brain damage occurs.
The new strategy merges Circular Genomics’ blood‑based biomarker assay with Altoida’s digital assessment platform. The blood test, which analyzes DNA methylation patterns linked to Alzheimer’s, is performed in a standard laboratory. The cognitive app, available on smartphones, evaluates memory, attention, and problem‑solving skills in a brief session. Together, they provide a complementary snapshot of a patient’s neurological health.
Alzheimer’s often progresses silently for years, so by the time symptoms prompt medical attention, the disease has usually advanced far enough that treatment options are limited. The combined test seeks to change that by detecting early molecular changes in the blood and subtle cognitive decline before patients notice problems. Circular Genomics’ technology relies on machine learning to interpret epigenetic markers, while Altoida’s app uses artificial intelligence to compare a user’s performance against age‑matched norms. The dual‑modality approach is expected to improve diagnostic accuracy and reduce false positives.
The blood assay screens for specific methylation signatures that correlate with amyloid and tau pathology in the brain. When a sample shows an elevated risk score, the patient is invited to complete the Altoida app. The app administers tasks that probe executive function, working memory, and visual processing. Results are automatically uploaded to a secure cloud, where an algorithm integrates both data streams. If both the blood and app indicate high risk, clinicians receive a consolidated report that can trigger further imaging or clinical trials.
Can This Approach Replace Existing Screening Methods?
„We’re combining the best of biology and digital medicine,” said a spokesperson for Circular Genomics. „The blood test gives us a molecular window into the brain, while the app captures real‑time cognitive performance. Together, they provide a more complete picture than either could alone.” Altoida’s lead scientist added, „Our platform is designed for quick, repeatable testing, which is essential for monitoring disease progression over time.”
Clinical trials are underway to validate the combined test’s predictive power. Early results suggest that the dual approach detects Alzheimer’s pathology up to five years before conventional clinical diagnosis. Researchers hope the method will also identify individuals who could benefit from preventative therapies currently in development.
The new test does not aim to replace established procedures such as PET imaging or cerebrospinal fluid analysis. Instead, it serves as an accessible, low‑cost screening tool that can be administered in primary care settings or even at home. By flagging high‑risk individuals early, the test could streamline referral pathways to specialist centers and accelerate enrollment in clinical trials.
Health professionals are cautiously optimistic. „Screening with a blood test and a digital app is an exciting development,” said a neurologist not involved in the study. „If the data hold up, it could transform how we identify and manage Alzheimer’s disease.” However, experts also warn that further longitudinal studies are needed to confirm long‑term benefits and to understand how best to integrate the test into routine care.
Frequently Asked Questions
The collaboration between Circular Genomics and Altoida represents a growing trend toward multimodal diagnostics in neurodegenerative disease. By combining biological markers with behavioral data, researchers hope to overcome the limitations of single‑modality tests and to deliver earlier, more accurate diagnoses.
What is the cost of the combined test? The price will vary by region and insurance coverage, but both components are designed to be affordable. The blood assay is priced similarly to other routine lab tests, while the app is available for a modest subscription fee or free for clinical use.
How often should the test be repeated? Guidelines suggest annual screening for individuals over 60 or those with a family history of Alzheimer’s. Repeat testing can help track disease progression and assess treatment response.
Will the test detect all types of Alzheimer’s? The blood assay targets epigenetic changes most commonly associated with sporadic Alzheimer’s. While it may miss rare genetic forms, the combined approach still offers valuable early detection for the majority of patients.